Epstein-Barr virus (EBV) often accesses the central nervous system (CNS) where it may lead to blood 40 brain barrier (BBB) integrity disruption, facilitating the migration of immune cells into brain 41 parenchyma. Our aim was to study the association between cerebrospinal fluid (CSF) EBV DNA and 42
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remaining authors have no conflict of interest to declare. 35 36 37 EBV DNA was detectable in 25 (21.9%) naïve and 26 (16%) treated patients at low levels (<100 and 48 146 copies/mL). Naïve EBV+ subjects presented higher CSF HIV RNA, biomarkers (t-tau, p-tau, 49 neopterin) and higher rates of pleocytosis. Treated EBV+ individuals showed pleocytosis, higher CSF 50 HIV RNA, CSF to serum albumin ratio, IgG index and neopterin. No association was observed 51 between detectable CSF EBV DNA and the rate of CSF escape. In patients with plasma HIV RNA <20 52 copies/mL (n=97) CSF EBV DNA was detectable in 13 subjects (13.4%) and it was associated with 53 pleocytosis, higher CSF HIV RNA and neopterin levels. EBV DNA was detectable in a considerable 54 proportion of HIV-positive patients and it was associated with higher levels of CSF HIV RNA and 55 neuronal damage/inflammation biomarkers. The role of EBV reactivation in HIV-associated CNS 56 disorders warrant further studies. 57
Introduction 70
Epstein-Barr virus (EBV) or Human Herpesvirus 4 (HHV-4) is a widely disseminated gamma 71 herpesvirus capable to persist, lifelong and asymptomatically, in a latent infection in adults [1] . 72
Transmission of EBV is so efficient that by adulthood most (> 95%) of the world's population has been 73 infected [2] . 74 EBV may affect the central nervous system (CNS) and clinical manifestations were first noted in 1931 75 by Epstein and Johansen. Both primary infection and reactivation can cause neurological diseases and 76 central nervous system involvement occurs in 1 to 10% of the cases [3] . Individual state of 77 immunocompetence, age and comorbidities have been associated with the occurrence of neurological 78 complications that include: meningo-encephalites, cerebellitis, optic neuritis, cranial nerve palsy, 79 peripheral neuropathy, Alice in Wonderland syndrome, ataxia, chorea, post-infectious autoimmune 80 disorders, including Guillain-Barrè syndrome, acute disseminated encephalomyelitis (ADEM) and 81 transverse myelitis [3] [4] [5] . 82
Biopsy proven vasculitis due to EBV infection have been reported: perivascular inflammatory infiltrate 83 was dominantly composed of CD3+ and CD8+ T-lymphocytes and macrophages. Some of the CD3 84 positive cells were also EBV-encoded RNA-1 (EBER1) positive, one of the two small noncoding 85
In MS patients' brains, EBV infection in B cells seems to alters the ability of B cells to process and 87 present a pathogenetically relevant myelin autoantigen and expression of higher levels of costimulatory 88 molecules than healthy controls, suggesting an enhanced APC function of B cells in MS brains, leading 89
to an higher autoimmune risk [9] . EBV-positive B lymphocytes count in normal human brain is very 90 low, but is shown an higher cell number in HIV infected brains. In PCR-based studies and in situ 91 hybridation studies were shown a detection of EBV in both lymphomatoid tissue and in pleomorphic 92 lymphoid infiltrates [10] . 93
Several works have established that EBV can infect macrovascular endothelial cells in human tissue 94 Reference values were as follows: t-tau [<300 pg/mL (in patients aged 21-50), <450 pg/mL (in patients 128 aged 51-70) or <500 pg/mL in older patients], p-tau (<61 pg/mL), 1-42 beta amyloid (>500 pg/mL), 129 neopterin (<1.5 ng/mL) and S100B (<380 pg/mL) [18] . Two hundred and eighty one adult patients were included. 111 (40.5 %) patients were naïve for 141 combination antiretroviral treatment (cART); baseline and immune-virological characteristics, 142 stratified by cART use, are shown in Table 1 . Lumbar punctures were performed before starting 143 antiretroviral treatment in naïve late presenting subjects (CD4+ T lymphocytes <100/uL) or in 144 symptomatic treated patients with cognitive disorders, headache or other neurological complaints. 145 CSF EBV DNA was detectable in 25 naïve (21.9%) and 26 treated (16%) patients with median values 146 of <100 (<100-234) and 146 (<100-612) copies/mL respectively. Virological, neuronal damage and 147 inflammation biomarkers stratified by cART use and CSF EBV detection are shown in Table 2 . 148 Naïve patients with detectable EBV DNA had higher CSF HIV viral load (4.2 vs. 3.7 log 10 copies/mL, 149 p=0.010); CSF to plasma HIV RNA ratios (25 vs. 4%, p=0.025), higher rates of pleocytosis (52% vs. 150 12.6%, p<0.001), CSF neuronal damage biomarkers t-tau (233 vs. 114 pg/mL, p=0.002), p-tau (38 vs. 151 29 pg/mL, p=0.051) and neopterin (9.25 vs. 2.02 ng/mL, p=0.001) (Figure 1 and 2, above) . The rate of CSF escape was similar in EBV-positive naïve (8.3% vs. 4.5%, p=0.607) and treated 158 patients (28% vs. 23.3%, p=0.615). 159
In plasma controllers (HIV RNA <20 copies/mL, n=97) CSF EBV DNA was detectable in 13 160 individuals (13.4%): it was associated with pleocytosis (50% vs. 8.4%, p=0.001), higher CSF HIV 161 RNA in those with detectable viral load (2.28 vs. 1.85 Log 10 copies/mL, p=0.011) and higher CSF 162 neopterin levels [2.81 ng/mL vs. 0.77 ng/mL, p=0.012] (Figure 3 ). In CSF controllers (CSF HIV RNA 163 <20 copies/mL, n=84) CSF EBV DNA was detectable in 10 individuals (11.9%): it was associated with 164 pleocytosis (66.6% vs. 6.9%, p<0.001) and border-line higher CSF neopterin (3. Several studies reported the role of EBV in immunocompromised patients and they showed that the 174 detection of EBV DNA in the CSF is a good marker of primary central nervous system lymphoma 175 (PCNSL, with sensitivity and specificity of 70% and 80%) [19] [20] [21] [22] . Some studies reported 176 the development of PCNSL in HIV-infected EBV-positive patients [23] [24] [25] [26] . [31] . Our data seem to confirm this hypothesis since both 185 naïve and treated patients present higher CSF HIV viral loads (and CSF to plasma HIV RNA ratios) 186
and white blood cells. Additionally cART-treated patients with detectable CSF EBV DNA showed 187 higher CSF to albumin ratios supporting a potential role in the persistence of BBB damage. The latter 188 has been shown to be a prevalent feature of patients with dementia, to persist in some subjects despite 189 treatment and to be associated with markers of neuronal damage and inflammation [ In a recent study that analyzed 108 gut biopsies collected from 19 HIV-infected and uninfectedparticipants, CMV and EBV were detected in more than 70% of samples but more 197 commonly in HIV-positive subjects [41] . While the negative effects of sporadic or continuous CMV 198 replication are well-known, there is still uncertainty on the role of EBV in chronic immune activation. 199
Additionally EBV may have a role in suppressing the CNS immune system and therefore maintain an 200
incomplete T-cell mediated inflammatory response; this may be achieved through the expression of 201 viral genes encoding for proteins with immunoevasin-like function. This may translate into higher rates 202 of pleocytosis but with less inflammatory activity [42] [43] . On the other hand our EBV-positive treated 203 patients showed lower CD4 counts thus suggesting that immune control may be needed in order to 204 restore a partial control on EBV low level replication. 205
Some limitations of this study should be acknowledged including the low sample size, the lack of a 206 control group and the lack of plasma EBV DNA measurements. Additionally our cohorts include 207 several patients with very low nadir CD4 cell counts and heterogeneous clinical conditions: the same 208 effect may not be observed in less advanced individuals. 209
In conclusion we reported for the first time the prevalence of EBV detection in the CSF of HIV-210 positive patients without lympho-proliferative disorders. Besides we observed that naïve subjects with 211 detectable CSF EBV DNA had a higher HIV viral load and higher markers of neuronal damage and 212 inflammation; in treated individuals despite a higher HIV viral load we report a higher prevalence of 213 blood brain barrier damage, pleocytosis and immune activation. Further studies are warranted for 214 understanding the contribution of EBV to HIV-associated CNS disorders. DNA on CSF and cART. "CSF" cerebrospinal fluid, "CSAR" Cerebrospinal fluid Serum Albumin 236
Ratio, "BBBi" Blood Brain Barrier impairment, "t-tau" total tau, "p-tau"phosphorylated tau, "Aβ1-42" 237 1-42 beta amyloid, "S100B" S100 Beta. "n.s." non significant (p values >0.05). 
